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ARTICLE
A Genome-wide Association Study
of Dupuytren Disease Reveals
17 Additional Variants Implicated in Fibrosis
Michael Ng,1 Dipti Thakkar,1 Lorraine Southam,2,3 Paul Werker,4 Roel Ophoff,5 Kerstin Becker,6,7
Michael Nothnagel,6 Andre Franke,8 Peter Nu¨rnberg,6,7 Ana Isabel Espirito-Santo,1 David Izadi,1
Hans Christian Hennies,6,7,9 Jagdeep Nanchahal,1,10 Eleftheria Zeggini,2 and Dominic Furniss1,10,11,*
Individuals with Dupuytren disease (DD) are commonly seen by physicians and surgeons across multiple specialties. It is an increasingly
common and disabling fibroproliferative disorder of the palmar fascia, which leads to flexion contractures of the digits, and is associated
with other tissue-specific fibroses. DD affects between 5% and 25% of people of European descent and is the most common inherited
disease of connective tissue. We undertook the largest GWAS to date in individuals with a surgically validated diagnosis of DD from the
UK, with replication in British, Dutch, and German individuals. We validated association at all nine previously described signals and
discovered 17 additional variants with p % 5 3 108. As a proof of principle, we demonstrated correlation of the high-risk genotype
at the statistically most strongly associated variant with decreased secretion of the soluble WNT-antagonist SFRP4, in surgical spec-
imen-derived DD myofibroblasts. These results highlight important pathways involved in the pathogenesis of fibrosis, including
WNT signaling, extracellular matrix modulation, and inflammation. In addition, many associated loci contain genes that were hitherto
unrecognized as playing a role in fibrosis, opening up new avenues of research that may lead to novel treatments for DD and fibrosis
more generally. DD represents an ideal human model disease for fibrosis research.Introduction
Dupuytren disease (DD [MIM: 126900]) is a progressive
fibroproliferative disease of the palmar fascia and the
most common inherited disorder of the connective tissue.
It is the most frequent example of a tissue-specific fibrotic
disease: others include pulmonary, renal, hepatic, and skin
fibrosis. It is accepted that there are common features of all
fibrotic diseases, but some pathologic pathways are likely
to be tissue specific.1
DD is characterized by the initial development of myofi-
broblast-rich nodules in the palm of the hand. These myo-
fibroblasts express alpha-smoothmuscle actin (a-SMA) and
secrete types III and I collagen, leading to the formation of
abnormal cords in the palm of the hand. In a proportion of
people with DD, the myofibroblasts cause contraction,
leading to flexion contractures of the involved digits and
subsequent functional impairment.2,3 As the hand is the
sensorimotor end-organ of the upper limb, impairment
here has a disproportionate effect on the quality of life of
the individual.4 Additionally, because DD is associated
with other forms of fibrosis, it may serve as an ideal human
model system for fibrotic disease, and the routine excision
of tissue as a part of treatment facilitates experimental
medicine studies.51Nuffield Department of Orthopaedics, Rheumatology, andMusculoskeletal Sci
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ulations of European descent, and there is evidence that
the prevalence is increasing.6–8 The mainstay of treatment
for DD is surgery, though newer modalities are increasing
in popularity. Despite this, complications and recurrence
of disease are both common, even after adequate primary
treatment.9,10
DD has a substantial heritable component. A twin study
from Denmark estimated the heritability of DD at 80%11
and a sibling recurrence study from the UK estimated the
lS to be 4.48, confirming a strong genetic predisposition
to DD.12 Furthermore, age at first surgical intervention is
significantly younger in those with a positive family
history.13 Similarly, there is evidence that multiple non-ge-
netic factors, such as smoking, alcohol intake, diabetes,
and hyperlipidemia, also play a role in disease develop-
ment.14
We have previously undertaken a pilot GWAS in 960
Dutch DD-affected individuals to begin to delineate the
common genetic variation underlying this predisposition.
This defined nine susceptibility loci and revealed the hith-
erto unsuspected importance of components of the WNT
signaling pathway in the pathogenesis of DD.15 To boost
power for the detection of common-frequency signals,
here we undertook a 4-fold larger GWAS in 3,871 UKence, University of Oxford, Botnar Research Centre,Windmill Road, Oxford
inxton, Cambridge CB10 1SA, UK; 3Wellcome Trust Centre for Human Ge-
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individuals with surgically validated DD. Replication of
significant and suggestive loci was performed in a total of
4,041 surgically validated DD-affected case subjects from
the UK, the Netherlands, and Germany.Material and Methods
Ethical Approval
The study was approved by the Research Ethics Committee or
equivalent at all institutions where the work was carried out:
Oxfordshire Research Ethics Committee B/09/H0605/65 for the
British Society for Surgery of the Hand Genetics of Dupuytren’s
Disease (BSSH-GODD) study (UK), Medical Ethics Committee
(METc) 2007/067 for the Genetic Origin of Dupuytren Disease
(GODDAF) Study (the Netherlands), and University of Cologne
14/292 for the German Dupuytren Study (Germany). Informed
consent was obtained from all subjects.Phenotype Definition and Study Populations
We used samples from three European countries for this study. In
all cohorts, the DD-affected case subjects were individuals who
had undergone surgical treatment for their disease. The UK cohort
consisted of a total of 5,408 case subjects from the BSSH-GODD
Study and 9,961 population-based control subjects from the
United Kingdom Household Longitudinal Study (UKHLS), which
were divided into 4,891 control subjects for the discovery phase
and 5,070 control subjects for the replication phase. The Dutch
cohort consisted of 2,195 case subjects from the GODDAF Study
and 1,983 control subjects from the Lifelines cohort study. The
German cohort consisted of 768 case subjects from the German
Dupuytren Study and 1,353 control subjects from the PopGen
and KORA studies. The cohorts included all samples analyzed in
our previous GWAS.15Biological Samples
For the BSSH-GODD cohort, salivary samples were collected using
the Oragene-OG250 salivary DNA collection kit (DNA Genotek).
DNA was extracted according to manufacturer’s instructions and
stored at 80C. Diseased fascial samples removed at surgery
were immediately placed in EMEMmedia (Lonza) and transferred
by overnight courier to our laboratory.
The UK Household Longitudinal Study is a stratified clustered
random sample of households representative of the UK popula-
tion, led by the Institute for Social and Economic Research at
the University of Essex and funded by the Economic and Social
Research Council. Blood was taken and DNA isolated by standard
methods. The genome-wide scan data were analyzed and depos-
ited by the Wellcome Trust Sanger Institute. Information on
how to access the data can be found on the Understanding Society
website.
For the GODDAF study, case subjects were identified from plas-
tic surgery clinics within the Netherlands, and DNA and pheno-
type data were obtained as previously described.15
LifeLines is a population-based cohort study based in the
Netherlands and has been previously described.16 For the purpose
of this study, DNA samples from participants, age- and sex-
matched to the GODDAF case subjects, were isolated (project
number OV14_0257).
For the German Dupuytren study cohort, blood samples were
collected from case subjects from Germany and Switzerland by418 The American Journal of Human Genetics 101, 417–427, Septemthe German Dupuytren Study Group13 and DNA was extracted
with standard procedures. 1,353 control subjects were obtained
from the Popgen and KORA studies.
Genotyping, Association Analysis, and Imputation
We genotyped 4,201 UK DD-affected case subjects using Illumina
HumanCoreExome arrays at the Wellcome Trust Sanger Institute
comprising 538,448 SNPs. The data were called using the Illumina
GenCall algorithm. Quality control and association analyses were
performed in PLINK v.1.9 and R v.3.3.1. We initially performed
sample-level quality control (Figure S1). Briefly, we first removed
all SNPs with a call rate < 90%. We standardized the output data
to NCBI build 37 (hg19) and the strand alignment using scripts
provided by Dr. William Rayner. We then removed 242 samples
with one or more of the following properties: call rate < 98%; het-
erozygosity > 3 standard deviations from the mean; different ge-
notype-derived sex and reported sex; or failure of genotyped
SNPs to match the pre-GWAS Sequenom fingerprinting. We
merged our data with publically available data from the 1000 Ge-
nomes Project and performed principal components analysis
(PCA) to define (and remove from further analysis) those people
who were ethnic outliers by visual inspection (Figure S2).
We then performed SNP-level quality control on this sample set.
Briefly, we excluded SNPs with call rate < 98%, those with Hardy-
Weinberg equilibrium (HWE) p < 0.0001, and those with a cluster
separation score of < 0.4. We also removed non-autosomal SNPs
and those that were duplicated.
This generated a final set of 3,959 case subjects genotyped at
494,982 SNPs. From the UKHLS control subjects we selected
4,891 individuals genotyped at 525,314 SNPs after identical
quality control. We then combined these control subjects with
our case subjects. From this combined dataset, we further excluded
86 case subjects and 202 control subjects from a total of 604
related individuals by average identity-by-descent allele sharing
(PiHATR 0.185 in PLINK), 1 sample due to poor genotype calling,
and a further 4 ethnic outliers, leaving 3,871 case subjects and
4,686 control subjects for the association analysis. Here we report
on the analysis of common variants within this cohort: 238,825
SNPs withminor allele frequencyR 0.05, as less common variants
were poorly called.
For the discovery phase, we performed association analysis us-
ing logistic regression with sex and the first two principal compo-
nent (PC1 and PC2) of the PCA as covariates. We did not use
further principal components in our regression model as after
adjustment for PC2, we saw no further separation of distinct
subsets, and the genomic inflation factor did not decrease further
(lGC unadjusted ¼ 1.104; adjusted for PC1 lGC ¼ 1.089; adjusted
for PC1 and PC2 lGC ¼ 1.089; PC1, PC2, and PC3 lGC ¼ 1.090).
We calculated this overdispersion factor of association test statis-
tics (lGC) using observed versus expected p values, and adjusted
for sample size by calculating l1000
17 (Figure S3). Conditional
analysis was performed at each associated locus, again using logis-
tic regression conditioning on themost statistically associated SNP
at each locus. If a second independent signal was detected
(p% 5.0 3 108), we conditioned on that SNP, repeating the pro-
cess until no further independent associations were evident.
We selected SNPs for replication that showed a putative associa-
tion in the discovery cohort with p % 1 3 105 (Table S1). The
integrity of each of these associations was confirmed by manual
inspection of the genotyping intensity plot (Figure S4).
For replication, additional UK case subjects and Dutch case and
control subjects were genotyped at the prioritized SNPs using theber 7, 2017
Sequenom MassARRAY platform. German case and control sub-
jects were previously genotyped on the Affymetrix Human SNP
Array 6.0. Where no direct or tag SNP was available on the Affyme-
trix platform, German case and control subjects were genotyped
using TaqMan probes (Table S1). SNPs with call rate < 90% or
SNPs with deviation from HWE (p < 0.0001) were removed, leav-
ing 46 (31 in the German cohort, 41 in the Netherlands cohort,
and 42 in the UK cohort) in the final dataset. 246 samples were
removed due to call rate < 90%, and 70 samples were removed
due to sex mismatch between self-reported data and genotyping
result. SNP rs2598107 was separately replicated only on the
UK cohort, 38 samples of which were removed due to call
rate < 90%. The remaining UKHLS control subjects were again
genotyped on the Illumina HumanCoreExome platform and un-
derwent QC as described above. We used multiple genotyping
platforms in the replication phase, so constructed Forest plots in
R to check for heterogeneity. Since our replication signals were
in the same direction and of similarmagnitude to our discovery re-
sults, it is unlikely that genotyping artifact was responsible for the
observed associations (Figure S5).
For association analysis of the replication phase, we performed
logistic regression and used sex as a covariate. The Breslow-Day
test was used to test for heterogeneity. We performed a fixed-
effects meta-analysis of discovery and replication phase using
the inverse variancemethod, assuming all studies share a common
true effect size at each locus. The explained heritability for
Dupuytren disease was estimated using the GCTA package.18
For imputation, we phased our dataset using SHAPEIT2.19 The
phased dataset was submitted to the Haplotype Reference Con-
sortium imputation service, utilizing the Sanger server and the
standard PBWT pipeline.20 Imputed data were subjected to quality
control. We removed SNPs with info score < 0.3, MAF < 1%, or
significant deviation from Hardy Weinberg equilibrium (p < 1 3
106). We used SNPTEST v2.5.221 to calculate the Bayes factor for
each SNP with the assumption that there was only one causal
SNP per associated region, and the additivemodel of prior distribu-
tion. For regions that contained two index SNPs, we identified the
BF for the second index SNP by conditioning on the first index
SNPs. Posterior probability was defined as Bayes factor for SNPk
divided by the summation of the BF for every SNP in the selected
region, 500 kb upstream and downstream of the index SNP, as pre-
viously described.22 99% credible sets were constructed by sum-
ming the ranked posterior probability of every SNP within each
associated region until the total reached 0.99.Tissue Culture
Primary cells were disaggregated from fresh surgical tissue samples
using 300 units/g type II collagenase at 1 mg/mL (Worthington
Chemical) in DMEM (Lonza) supplemented with 5% FBS (Lab-
tech) overnight at 37C with 5% CO2. After incubation, cells
were filtered using 40 mm tissue culture strainer, pelleted, and
cultured on 10 cm2 Petri dishes. Primary myofibroblasts were
cultured in DMEM supplemented with 10% FBS (Labtech),
1% penicillin/streptomycin, and 13 Glutamax (ThermoFisher
Scientific).Immunocytochemistry
Diseased, surgically resected palmar fascia was disaggregated as
previously described,23 and myofibroblasts were seeded on
35 mm FluoroDish tissue culture dishes (World Precision Instru-
ments) at 50,000 cells per dish. Cells were fixed in 4% formalde-The Americanhyde and permeabilized using 0.1% triton X. SFRP4 was stained
using goat anti-SFRP4 primary IgG antibody (AF1827, R&D Sys-
tems) and rabbit anti-goat IgG Alexa Fluor 633 (A-21086, Thermo-
fisher Scientific). Filamentous actin and nuclei were stained using
Acti-stain 488 phalloidin (Cytoskeleton Inc.) and Hoechst 33342
(Thermofisher Scientific). Fluorescence images were acquired us-
ing a confocal laser scanning microscope (Zeiss LSM 710) with a
403 objective.Immunohistochemistry
Dupuytren fascia tissue and palm skin were processed by the
Kennedy Institute of Rheumatology histopathology service unit.
Briefly, samples were dehydrated in a tissue processor Tissue Tek
VIP (Sakura, 60320296-1210) and paraffin embedded with Tis-
sue-Tek TEC (Sakura 5230-1177). 5 mM sequential sections were
obtained and mounted onto Surgipath X-tra Adhesive slides
(Leica,Milton Keynes) or Polysine slides (ThermoFisher Scientific).
Slides were baked at 60C for 60min and submerged in a FLEX TRS
filled PT Link machine for deparaffinization and antigen retrieval.
Immunostaining was performed using an Autostainier Link 48
machine with rabbit anti-SFRP4 primary antibody (Abcam cat#
AB32784; RRID: AB_2187103) or rabbit anti-WNT3A primary anti-
body (GTX128101, GeneTex). Antigen binding was visualized
using FLEX 3,30-diaminobenzidine (DAB) substrate working solu-
tion andwas counterstainedwith hematoxylin (Dako). Flex Rabbit
isotype control (Dako) was used as a reference for non-specific an-
tigen binding. All images were obtained using a Zeiss AXIO Imager
microscope and 203 objective.RNA Expression
For basal expression level experiments, myofibroblast cells of
defined genotype at rs16879765 were thawed from storage in
liquid nitrogen, then plated on 6-well plates at a density of
1 3 105 cells per well or 24-well plates at 5 3 104 cells per well,
without antibiotics. RNAwas extracted after 24 hr of culture using
Trizol (ThermoFisher Scientific) and Direct-zol RNA MiniPrep kit
(Zymo Research) according to the manufacturer’s instructions.
Reverse transcription was performed using High-Capacity RNA-
to-cDNA kit (ThermoFisher Scientific) according to the manufac-
turer’s instructions. Quantitative PCR (qPCR) was performed using
Taqman Advance Master Mix with pre-designed Taqman probes
(Thermo Fisher Scientific) for genes of interest, and control gene
18S. Relative quantification over control genes was calculated us-
ing the DCt method. The statistical significance between means
was tested using a two-tailed Student’s t test, with equal variances
assumed. Each experiment was conducted in triplicate on cells
derived from independent individuals (CC n ¼ 10; CT n ¼ 9; TT
n ¼ 7). A p value of less than 0.05 was considered significant.
For stimulation experiments, primary cells derived from surgi-
cally resected DD fascia were cultured as described above. Cells
were plated on 6-well plates at 1 3 105 cells per well and serum
starved for 24 hr. Cells were then stimulated with vehicle control
or a combination of recombinant WNT3A (200 ng/mL), SFRP4
(8 mg/mL), or DKK1 (100 ng/mL). Cells were harvested at 48 hr,
and relative expression of genes of interest was determined by
qPCR using Taqman probes as described above. Results were calcu-
lated using the DDCt method and are expressed as relative
expression compared to WNT3A stimulation alone, which was
normalized to 18S as described above. Each experiment was per-
formed on cells derived from four independent individuals. The
statistical significance between means was tested using two-tailedJournal of Human Genetics 101, 417–427, September 7, 2017 419
Figure 1. Manhattan Plot for the Discovery Association Analysis
The horizontal blue line represents p ¼ 1 3 105 and the horizontal red line indicates p ¼ 5 3 108. Variants colored in cyan are sug-
gestive of association (p% 1 3 105) and those colored red have genome-wide significant association (p% 5 3 108). The nine previ-
ously reported associated loci are indicated by an open circle surrounding the SNP.Student’s t test with equal variance assumed, and a p value of less
than 0.05 was considered significant.
SFRP4 Protein Expression
Intracellular and extracellular protein expression of SFRP4 was
determined using the sandwich ELISA kit (Phadia Gmbh) provided
by Dr. Hoffmann, University of Freiburg.24 Intracellular protein
was collected by cell scraping in 100 mL of RIPA buffer, supple-
mented with 1% protease inhibitor cocktail (PIC). Total protein
level was determined using bicinchoninic acid assay (Millipore).
We performed the ELISA according to manufacturer’s instructions.
All wash steps specified below were performed using the wash
buffer provided by the manufacturer unless stated otherwise. Sam-
ples were diluted 1 in 10 with the sample diluent and loaded onto
SFRP4 antibody-coated 8-well strips. After 60 min of incubation at
room temperature, the solution was discarded and the wells were
washed three times. 100 mL of primary antibodies (Phadia Gmbh)
was added to the wells, followed by 60 min incubation at room
temperature. The solution was removed, and the wells were
washed three times. 100 mL of conjugate was added and incubated
for 30min of incubation at room temperature. After discarding the
conjugate and washing the wells three times, 50 mL of HRP sub-
strate, 3,30,5,50-Tetramethylbenzidine (TMB) was added. The reac-
tion was then terminated using the stop solution after 30 min of
incubation in the dark. The absorbance of the solution was deter-
mined using photometer at 450 nm with reference wavelength at
620 nm. Absolute concentration was calculated using the standard
curve generated. After an initial range-finding experiment, the
time point of 7 days was selected for the full experiment. Each
experiment was repeated in duplicate on cells from independent
individuals (CC n ¼ 9; TT n ¼ 6), at 7 days from the beginning
of culture. The statistical significance between means was tested
using two-tailed Student’s t test, and a p value of less than 0.05
was considered significant.Results
GWAS
In the GWAS discovery phase, we used the Illumina
HumanCoreExome array to test 238,825 common-fre-
quency variants (MAF R 0.05) for association with DD in420 The American Journal of Human Genetics 101, 417–427, Septem3,871 UK case subjects and 4,686 UK control subjects, after
quality control. This yielded genome-wide significant asso-
ciations (p% 5 3 108) at 14 variants, including 8 of the 9
previously reported loci (Figure 1).
In the replication phase, we genotyped 45 SNPs with
p % 1 3 105 in the discovery set, in a total of 4,041 case
subjects and 8,251 control subjects from the UK, the
Netherlands, and Germany. In addition, there were a
further four SNPs with suggestive association (p % 1 3
105) and one with genome-wide significant association
(rs246105, frequency 20.1%, OR ¼ 0.796, p ¼ 1.34 3
108) for which we were unable to design an appropriate
assay (Tables 1 and S1). After fixed-effects meta-analysis,
we confirmed association at all 9 previously reported loci
and defined 15 further loci with genome-wide significant
evidence of association (Table 1; Figure S6).
Conditional analysis at all associated loci confirmed two
independent signals at two loci. On chromosome 7, after
conditioning on rs16879765, rs2598107 showed residual
evidence of association (r20, frequency 44.7%, OR ¼
1.48, pcond ¼ 6.85 3 1031). Similarly, on chromosome 8,
after conditioning on rs629535, rs2912522 showed resid-
ual evidence of association (r20, frequency 19.7%, OR ¼
0.73, pcond ¼ 1.31 3 1014; Table 1).
To further characterize the genetic architecture of DD,
we tested first the contribution of all autosomal com-
mon-frequency variants (MAF R 0.05) and second the 26
genome-wide significant variants alone to trait variance us-
ing genome-wide complex trait analysis (GCTA)25 and esti-
mated them to be 53.1% and 11.3%, respectively.
Imputation and Construction of 99% Credible Sets
We imputed our dataset using the Haplotype Reference
Consortium resource. We calculated single SNP Bayes Fac-
tors (BF) for 7,218,238 SNPs within our imputed dataset,
containing variants that passed our QC criteria. Variants
with the highest BF within each associated region from
our meta-analysis were used as the index SNP for the con-
struction of 99% credible sets. Similar to our primaryber 7, 2017
Table 1. SNPs Significantly Associated with Dupuytren Disease (p % 5 3 108)
Chromosome Positiona rsID Allele EAFb
Discovery Replication Meta-analysis Selected Nearby Genes
p OR p OR p OR (95% CI)
1 22698447 rs7524102 G 0.214 7.68 3 1012 1.332 6.43 3 105 1.448 3.00 3 1015 1.351 1.254–1.456 WNT4, ZBTB40
1 162672011 rs17433710 C 0.12 9.13 3 107 0.791 3.73 3 105 0.833 1.99 3 1010 0.813 0.763–0.867 DDR2, HSD17B7
5 108672946 rs246105c T 0.201 1.34 3 108 0.796 – – – – – PJA2
6 149797014 rs394563 T 0.411 2.03 3 108 0.828 1.02 3 1010 0.827 1.14 3 1017 0.828 0.793–0.864 ZC3H12D, TAB2, SUMO4
7 3318658 rs10276303 T 0.26 2.89 3 108 0.817 6.00 3 109 0.831 9.63 3 1016 0.825 0.787–0.865 SDK1, CARD11
7 37973014 rs2598107d T 0.447 1.11 3 1030 1.478 1.82 3 1015 1.475 1.55 3 1044 1.477 1.399–1.56 SFRP4, EPDR1
7 37989095 rs16879765 T 0.178 7.15 3 1041 1.926 2.82 3 1042 1.837 3.38 3 1081 1.877 1.759–2.002 SFRP4, EPDR1
7 116892846 rs38904 C 0.464 1.02 3 1011 1.254 6.52 3 1013 1.253 4.24 3 1023 1.253 1.199–1.311 WNT2
8 25845675 rs10866846 A 0.421 3.14 3 1011 1.249 1.78 3 106 1.148 1.75 3 1015 1.19 1.14–1.242 EBF2
8 69992380 rs2912522d G 0.201 1.29 3 1016 0.72 3.26 3 1014 0.751 4.09 3 1029 0.736 0.698–0.777 LOC100505718
8 70007938 rs629535 T 0.351 2.84 3 1028 1.477 1.17 3 1015 1.275 4.31 3 1040 1.357 1.297–1.42 LOC100505718
8 109228008 rs611744 G 0.402 3.70 3 1019 0.737 9.92 3 1016 0.794 1.15 3 1032 0.77 0.737–0.804 EIF3E, RSPO2
8 145504343 rs7838717 T 0.405 2.55 3 106 1.173 3.91 3 109 1.188 4.81 3 1014 1.182 1.131–1.234 BOP1, HSF1, DGAT1
9 1201156 rs12342106 A 0.308 9.76 3 1012 1.289 6.40 3 1016 1.29 3.78 3 1026 1.29 1.23–1.352 LINC01230,DMRT1,DMRT2,DMRT3
13 44842503 rs9525927 G 0.167 5.80 3 106 0.823 6.76 3 106 0.842 1.82 3 1010 0.833 0.788–0.881 MIR8079, SMIM2, SERP2
14 23312594 rs1042704 A 0.248 8.72 3 1013 1.326 1.12 3 108 1.213 2.49 3 1019 1.259 1.198–1.324 MMP14
14 51074461 rs1032466 C 0.306 4.90 3 109 0.812 6.82 3 1010 0.824 1.96 3 1017 0.818 0.781–0.857 ATL1, MAP4K5, SAV1
15 56229760 rs1509406 G 0.356 4.03 3 106 1.175 1.41 3 105 1.154 2.59 3 1010 1.164 1.110–1.22 NEDD4
15 68628163 rs2306022 T 0.11 7.59 3 106 1.286 2.57 3 106 1.266 8.70 3 1011 1.275 1.185–1.372 ITGA11
15 89238184 rs6496519 T 0.164 9.35 3 108 0.795 1.42 3 1010 0.789 7.18 3 1017 0.791 0.749–0.836 ISG20, ACAN, AEN
16 75506593 rs977987 G 0.403 6.24 3 107 1.184 8.84 3 105 1.12 4.82 3 1010 1.146 1.098–1.197 CHST6, TMEM170A, CFDP1
18 9762933 rs9951109 C 0.133 1.24 3 107 0.776 8.89 3 105 0.852 1.43 3 1010 0.82 0.771–0.871 RAB31
19 57678194 rs11672517 A 0.284 1.42 3 1013 1.331 2.71 3 105 1.384 1.99 3 1017 1.341 1.254–1.435 DUXA, ZIM3, ZNF264
20 38300807 rs6016142 T 0.132 1.19 3 106 1.282 1.98 3 108 1.274 1.15 3 1013 1.277 1.197–1.363 LINC01370, LOC339568
20 39320751 rs6102095 A 0.125 8.54 3 107 0.792 1.10 3 1013 0.71 1.96 3 1018 0.748 0.701–0.799 MAFB
22 46459132 rs7291412 T 0.413 1.24 3 1015 1.316 1.14 3 1016 1.269 1.53 3 1030 1.288 1.234–1.345 WNT7B, MIRLET7BHG
aBased on human genome build hg19.
bThe effect allele frequency (EAF) in the total cohort is shown, except for rs246105, where the effect allele frequency in the discovery set is shown.
cWe were unable to design an assay for this SNP in the replication phase.
dIdentified by conditional analysis.
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analysis, conditional analysis revealed the same two loci
with two independent signals. On chromosome 7, after
conditioning on rs117402009 (BF ¼ 9.87 3 1045), we
found residual evidence of association for rs2598100
(BFcond ¼ 7.293 1031), and on chromosome 8, after condi-
tioning on rs2472141 (BF ¼ 2.22 3 1028), we found resid-
ual association for rs2981040 (BFcond ¼ 1.75 3 1011). We
therefore constructed independent credible sets based
around each independent signal at these loci (Figure S7
and Table S2). Intriguingly, for one of the credible sets con-
structed, the genotyped SNP rs1042704 (BF ¼ 1.67 3 1010)
had a posterior probability greater than 0.99 and therefore
appears to be the causative allele at that locus. Overall, the
credible sets range in size from 1 to 293 variants, with a
median size of 27.5. Details of the 99% credible sets can
be found in Table S2 and Figure S7.
rs16879765
We further investigated the functional consequences of
the statistically most associated SNP from the direct geno-
typing, rs16879765, as a proof of principle that using my-
ofibroblasts from surgically resected DD tissue could help
define the causative gene at a particular locus. This SNP
is located in an intron of the gene EPDR1 and approxi-
mately 4 kb upstream of SFRP4 (MIM: 606570) (Figure 2A).
EPDR1 is a poorly characterized type II transmembrane
protein that shares some homology with ependymins
and protocadherins. EPDR1 has been shown to be upregu-
lated in CD34þ hematopoetic stem cells and colorectal
cancer cells.26,27 SFRP4 is a secreted protein with homology
to the membrane-bound WNT receptors FZD. It is thought
tomodulateWNTsignaling by competing forWNT ligands
with Frizzled receptors.28
We utilized myofibroblasts up to passage three derived
from surgically resected DD samples to study the geno-
type-specific expression of SFRP4 and EPDR1. The homozy-
gous high-risk (TT) genotype at rs16879765 showed
significantly greater SFRP4 expression compared to the
low-risk (CC) genotype, with the heterozygous state
showing intermediate expression levels. There was no
genotype-specific differential expression of EPDR1 (Fig-
ure 2B). Immunocytochemistry performed on disaggre-
gated primary cells from surgically resected DD tissue failed
to demonstrate EPDR1 expression but showed cytoplasmic
SFRP4 expression (Figure 2C). Furthermore, immunohisto-
chemistry confirmed expression of SFRP4 in fixed surgi-
cally resected fibrotic DD tissue (Figure 2D), but not in
palm skin or using isotype control antibody (Figure S8).
We used ELISA to examine the expression of SFRP4 protein
in DD-derived myofibroblasts. There was decreased accu-
mulation of extracellular SFRP4 from the high-risk geno-
type cells (Figure 2E), consistent with the role of SFRP4 as
a secreted WNT antagonist. As SFRP4 has been previously
shown to bind to WNT3A,29 we first examined WNT3A
expression by immunohistochemistry in our fixed surgical
specimens and showed expression in surgically resected
fibrotic DD tissue, but not in palm skin or using isotype422 The American Journal of Human Genetics 101, 417–427, Septemcontrol antibody (Figure S8). We then used recombinant
human WNT3A, SFRP4, or a combination of the two
proteins to stimulate DD-tissue-derived myofibroblasts,
palmar-skin-derived fibroblasts, and non-palmar-skin-
derived fibroblasts from four unrelated DD-affected indi-
viduals. We found no difference in expression of collagen
type I or type III in any of the cells tested. WNT3A selec-
tively increased the expression of a-SMA in the Dupuytren
myofibroblasts. Furthermore, WNT3A increased signaling
in both canonical and non-canonical WNT signaling path-
ways, as evidenced by increased AXIN2 (MIM: 604025) and
CTGF (MIM: 121009) expression, respectively30 (Figure 2F).
Interestingly, SFRP4 appeared to act as a selective antago-
nist of non-canonical signaling by WNT3A but had no sig-
nificant effect on canonical signaling (Figure 2G).Discussion
We have completed the largest GWAS to date in DD, the
most common inherited disorder of connective tissue.
Our results have almost tripled the known loci associated
with this localized fibrosis and have also highlighted the
role of fundamental biological processes in the pathophys-
iology of fibrosis, in the context of DD. Several associated
loci harbor potentially attractive drug targets and are the
subject of active further research. While we acknowledge
that the mechanistic link between associated SNPs and
pathophysiological function can often be obscure and re-
quires experimental validation, we think that certain bio-
logical processes deserve discussion.WNT Signaling
The importance of WNT signaling in fibrosis, as exempli-
fied by DD, has been confirmed by this work. All previ-
ously reported loci that harbor WNT pathway genes have
been replicated in this larger study, includingWNT ligands
WNT2, WNT4, and WNT7B, a co-signaling molecule
RSPO2, and WNT antagonist SFRP4.15
Our detailed functional studies on the statistically most
strongly associated variant (rs16879765) have suggested
that a subtle imbalance of WNT signaling contributes to
the fibrotic phenotype. We postulate that the decreased
SFRP4 secretion seen in individuals homozygous for the
high-risk allele at rs16879765 allows a subtle increase in
WNT3A signaling through the non-canonical pathway.
This could lead to greater a-SMA expression and hence
contraction of the DD cords.31 This contraction is charac-
teristic of the latter stages of DD and requires surgical
treatment.
Taken as a whole, our genetic results suggest that subtle
variations in the level of WNT signaling are likely to be
responsible for the fibrosis seen in DD. The genetic variants
cluster around ligands, a co-stimulatory molecule, and a
WNT antagonist. This contrasts with variants in the
WNT signaling pathway that predispose to cancer, which
tend to be downstream of the receptor and lead tober 7, 2017
Figure 2. The High-Risk Genotype at rs16879765 Is Associated with a Reduction in SFRP4 Protein Secretion and Reduces Inhibition of
Non-canonical WNT Signaling
(A) Annotated regional association plot for the 7p14.1 locus, generated using LocusZoom software.57 Recombination rates were derived
from HapMap data.
(B) qPCR of genotyped DD-derived myofibroblasts revealed that the high-risk TT genotype was associated with increased mRNA expres-
sion of SFRP4 (left) but not EPDR1 (right). Each experiment was conducted in triplicate on cells derived from independent individuals
(CC n ¼ 10; CT n ¼ 9; TT n ¼ 7). Error bars represent the standard error of the mean.
(C) Immunocytochemistry reveals robust expression of SFRP4 (red) in DD-derived myofibroblasts. Nuclei are stained blue, and F-actin is
stained green.
(D) Immunohistochemistry in fixed surgically resected DD fibrotic fascia confirms expression of SFRP4 (brown).
(E) ELISA of supernatant fromDD-derivedmyofibroblasts shows that decreased extracellular accumulation of SFRP4 protein is associated
with the high-risk TT genotype at rs16879765. Each experiment was repeated in duplicate on cells from independent individuals (CC
n ¼ 9; TT n ¼ 6), at 7 days from the beginning of culture. Error bars represent the standard error of the mean.
(F and G) WNT3A stimulation of DD-derived myofibroblasts upregulates both the canonical (AXIN2) and non-canonical (CTGF) path-
ways, and also upregulates the expression of a-smoothmuscle actin (ACTA2), while having no effect on the expression of b-actin (ACTB)
or collagen types I (COL1A1) or III (COL3A1). The addition of SFRP4 or non-specificWNT inhibitor DKK1 alone has no appreciable effect
on signaling or expression of any tested gene. The addition of SFRP4 in combination with WNT3A selectively inhibits signaling via the
non-canonical pathway, whereas DKK1 inhibits both canonical and non-canonical signaling. Each experiment was repeated in duplicate
on cells from independent individuals (CC n ¼ 9; TT n ¼ 6) at 7 days from the beginning of culture. *p < 0.05.receptor-independent signaling and unrestrained cellular
growth and proliferation.32 While DD does share some
clinical features with cancer, such as excess cellular prolif-
eration, abnormal extracellular matrix deposition,33 and
the tendency to recur after treatment, it is ultimately a
benign phenotype.
Extracellular Matrix Modulation
Fibrotic disease is characterized by abnormal and excessive
extracellular matrix (ECM) deposition.1 In DD, theThe Americanabnormal fibrotic cords are composed mainly of collagen,
with a higher type III to type I collagen ratio than in
unaffected palmar fascia.2 Several of our additional associ-
ated loci harbor genes that are known to interact with
and modulate the ECM: DDR2 (MIM: 191311) at chro-
mosome 1q23.3 (rs17433710, OR ¼ 0.81, pmeta ¼ 1.99 3
1010), MMP14 (MIM: 600754) at chromosome 14q11.2
(rs1042704, OR ¼ 1.26, pmeta ¼ 2.49 3 1019), ITGA11
(MIM: 604789) at chromosome 15q23 (rs2306022, OR ¼
1.28, pmeta ¼ 8.70 3 1011), ACAN (MIM: 155760) atJournal of Human Genetics 101, 417–427, September 7, 2017 423
chromosome 15q26.1 (rs6496519, OR ¼ 0.79, pmeta ¼
7.18 3 1017), and CHST6 (MIM: 605294) at chromosome
16q22 (rs977987, OR ¼ 1.15, pmeta ¼ 4.82 3 1010).
Discoidin domain receptor 2 (DDR2) is a membrane-
bound receptor tyrosine kinase that contains an extracel-
lular discoidin homology domain.34 The functional ligand
for DDR2 is fibrillar collagen (types I–III), though it has also
been shown to bind type X collagen.35–37 DDR2 has previ-
ously been shown to play a role in collagen production and
migration through the basement membrane by skin fibro-
blasts.38 Furthermore, DDR2 plays a complex role in liver
fibrosis. DDR2 expression is induced by acute liver injury
in a mouse model, and expression of a constitutionally
active form of DDR2 enhances proliferation and invasion
of hepatic stellate cells.39 However, in contrast to the acute
injurymodel, DDR2 knockoutmice aremore susceptible to
chronic inflammation and fibrosis in a carbon tetrachlo-
ride model of chronic liver injury.40 Intriguingly, this
increased susceptibility to chronic fibrosis is mediated in
part by attenuating the interaction of hepatic stellate cells
with macrophages, suggesting a link between DDR2 and
pro-inflammatory pathways (see below).
DDR2 expression has also been shown to be increased
both inmouse models of osteoarthritis (OA) and in human
OA.41 In this context, the effect of DDR2 is mediated by its
induction of matrix metalloproteinase 13 (MMP13), the
major MMP responsible for type II collagen degradation
in OA.42 Decreased expression of DDR2 in heterozygous
knockout mice lead to the attenuation of OA after joint
destabilization.43 This raises the possibility of cross talk
between DDR2 and MMP pathways that may be relevant
in DD pathogenesis. DDR2 represents an attractive thera-
peutic target in DD and other fibrotic diseases and is
currently under active investigation by several pharmaceu-
tical companies.44
Matrix metalloproteinase 14 (MMP14 or MT1-MMP) is a
type 1 transmembrane protein and member of the MMP
family of proteases, initially characterized for their ability
to degrade the extracellular matrix. MMP14 was the first
membrane-bound MMP to be discovered and was initially
characterized as a pro-MMP2 activator, though now at least
42 substrates have been defined, including fibrillar
collagen and the WNT antagonist DKK1.45 There is some
evidence for the involvement of MMP14 in DD pathogen-
esis. In clinical trials, broad-spectrum MMP inhibition
caused some individuals to develop DD.46 MMP14 is over-
expressed in DD nodules,47 and knockdown of MMP14 in
DD-derived cells reduced both contraction and MMP2
activation in vitro.48 Interestingly, knockdown of MMPs
including MMP14 did not change the rate of collagen
breakdown, suggesting that non-proteolytic effects of
MMP14 are responsible for the pro-fibrotic phenotype.
Further characterization of the mechanism of action of
MMP14 in DD may lead to the validation of this protein
as a therapeutic target in fibrosis.
ITGA11 encodes integrin alpha11, a member of the in-
tegrin family of cell-surface-adhesion receptors. These424 The American Journal of Human Genetics 101, 417–427, Septemtype I transmembrane proteins act as heterodimers
composed of an a and b subunit, and through binding to
the ECM transmit both mechanical and chemical signals
to the cell.49 Heterodimers consisting of integrin a11b1
are fibroblast-specific collagen receptors, which are me-
chanically induced, and regulate myofibroblast differentia-
tion. Furthermore, ITGA11 has recently been shown to be
overexpressed in lung samples from individuals with idio-
pathic pulmonary fibrosis.50 Also, a variant near PTK2 (en-
coding focal adhesion kinase [FAK] [MIM: 600758]) at
chromosome 8q24.3 showed suggestive evidence of associ-
ation in our discovery cohort (rs12677559, OR ¼ 0.86,
p ¼ 5.75 3 106; Table S3; Figure S9A), but we were unable
to design a suitable assay within the replication set. FAK is a
non-receptor tyrosine kinase that is an integral part of focal
adhesion structure51 and is phosphorylated in response to
integrin engagement.52 In a mouse model of hypertrophic
scarring, another example of a localized fibrosis, fibroblast-
specific FAK knockout attenuated both fibrosis and inflam-
mation (see below), emphasizing the importance of this
signaling pathway in fibrosis.53Inflammation
Chronic inflammation has long been recognized as a
key player in the pathogenesis of fibrosis in multiple
organs, including liver, kidney, lung, and heart.54 Recent
work has highlighted the important role of inflammation
in DD. In particular, tumor necrosis factor (TNF)—
signaling via the WNT pathway—was demonstrated to
selectively upregulate a-SMA and subsequent contractility
in palmar-skin-derived fibroblasts from DD-affected indi-
viduals compared to unaffected control subjects.23 While
our associated regions do not harbor many inflammatory
genes, they do indicate how this cross-talk between TNF
and WNT signaling might occur. MAP4K5 (MIM:
604923)—also known as germinal center kinase-related
(GCKR)—at chromosome 14q22.1 (rs1032466, OR ¼
0.82, pmeta¼ 1.963 1017) has been shown to be activated
by both TNF and WNT3A, and decreased expression of
MAP4K5 inhibits GSK3b phosphorylation and subsequent
b-catenin accumulation in B lymphocytes.55,56 This sug-
gests a key role for MAP4K5, integrating TNF and WNT
signaling in DD fibrosis.
In conclusion, we have described the largest-scale GWAS
to date in DD, a common disease that is a model human
fibrotic condition. We discovered 17 additional variants
predisposing to fibrosis, bringing the total described to
26. Analysis of heritability explained by these 26 variants
compared to all common autosomal variants in our study
suggests that there are many more common variants
affecting predisposition to DD and that larger studies
with greater power will detect further associated loci. We
characterized the subtle nature of the genetic predisposi-
tion at our statistically most associated locus, thereby iden-
tifying a potential therapeutic target. In addition, our
results have highlighted other specific biological pathwaysber 7, 2017
that are likely to play an important role in the pathogen-
esis of DD and in fibrosis more widely.
DD represents a human disease that is attractive for
early-phase trials of experimental therapeutics, owing to
the ready availability of affected individuals, ease of access
to affected tissues, and the excision of fibrotic tissue as
routine part of clinical care.Accession Numbers
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